Recursion Pharmaceuticals could benefit from FDA’s AI shift despite risks, with scalable tech and long-term potential. Find ...

Diabetic macular edema is a complication that develops from diabetic retinopathy, a widespread consequence of diabetes and a ...

Artificial Intelligence (AI) is no longer a futuristic idea in healthcare; it is reshaping the industry right now, and 2025 ...

Amgen AMGN reported first-quarter 2025 adjusted earnings of $4.90 per share, which beat the Zacks Consensus Estimate of $4.16 ...

Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease remains on track for topline data readout in the second quarter 2025 - - Tourmaline ...

CET - Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological diseases, today publishes its results for the year ending 31 December ...

In 2014, the clinical development success rate stood at 10.4%; just over one in every 10 drugs that entered a Phase I clinical ... clinical trials in a more cost-effective manner.

Topping the chart for off ... allowing for research and development costs. Big Pharma argues this is a huge financial burden. But is it really? Take pembrolizumab, a drug that uses an adapted ...

On a Thursday conference call with investors, Moderna CFO Jamey Mock outlined a roadmap for the mRNA specialist to lower its ...

23andMe's big push into drug development ... shown by our clinical and preclinical stage pipeline and will continue to pursue strategic opportunities to continue their development," said Wojcicki.

At this time, I'd like to welcome everyone to the Biogen first quarter 2025 earnings call and business update. (Operator Instructions). Today's conference is being recorded. Thank you. I would now ...

United Therapeutics’ UTHR first-quarter 2025 earnings of $6.63 per share beat the Zacks Consensus Estimate of $6.29. The ...